Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.

Advances in experimental medicine and biology - 1 Jan 2016

Naidoo Jarushka, Drilon Alexander

Abstract excerpt

KRAS-mutant lung cancers account for approximately 25% of non-small cell lung carcinomas, thus representing an enormous burden of cancer worldwide. KRAS mutations are clear drivers of tumor growth and are characterized by a complex biology involving the interaction between mutant KRAS, various growth factor pathways, and tumor suppressor genes. While KRAS mutations are classically associated with a significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Farnesyltranstransferase
Share to Heat-Shock Proteins
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins p21(ras)

Share to raf Kinases

Source

Identifiers

PMID: 26667343
DOI: 10.1007/978-3-319-24223-1_8

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.PMID 26667343Read ↗

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

New Horizons in KRAS-Mutant Lung Cancer: Dawn After DarknessSemantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSemantic proximity Read ↗

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.Semantic proximity Read ↗

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.Semantic proximity Read ↗

KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.Semantic proximity Read ↗

Treating KRAS -mutant NSCLC: latest evidence and clinical consequencesSemantic proximity Read ↗

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The genetics and biology of KRAS in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.